MY201954A - Pharmaceutical composition comprising nebivolol with improved dissolution rate - Google Patents
Pharmaceutical composition comprising nebivolol with improved dissolution rateInfo
- Publication number
- MY201954A MY201954A MYPI2018702352A MYPI2018702352A MY201954A MY 201954 A MY201954 A MY 201954A MY PI2018702352 A MYPI2018702352 A MY PI2018702352A MY PI2018702352 A MYPI2018702352 A MY PI2018702352A MY 201954 A MY201954 A MY 201954A
- Authority
- MY
- Malaysia
- Prior art keywords
- nebivolol
- pharmaceutical composition
- dissolution rate
- preparation
- pharmaceutically acceptable
- Prior art date
Links
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 title abstract 6
- 229960000619 nebivolol Drugs 0.000 title abstract 6
- 238000004090 dissolution Methods 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 238000002360 preparation method Methods 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 230000003113 alkalizing effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229960004796 rosuvastatin calcium Drugs 0.000 abstract 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000000080 wetting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a pharmaceutical composition having an improved dissolution rate of nebivolol. A pharmaceutical composition, containing nebivolol or a pharmaceutically acceptable salt thereof, an alkalizing agent, and a pharmaceutically acceptable additive, for prevention or treatment of cardiovascular diseases, does not cause a decrease in the dissolution rate of nebivolol and can significantly improve the dissolution rate, not only at low pH, such as pH 1.2, but also at a relatively high pH of 5 to 7, so that an improved therapeutic effect can be expected. In addition, the pharmaceutical composition can reduce the manufacturing cost since the micronization of nebivolol or the addition of a wetting agent is not required, and can minimize the occurrence of a deviation of bioavailability under fasting or fed condition since there is little deviation of the dissolution rate due to the pH change, thereby maintaining a constant pharmaceutical action, and thus, the pharmaceutical composition is very useful in the preparation of a nebivolol preparation or a composite preparation containing another active ingredient, such as rosuvastatin calcium.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160002626 | 2016-01-08 | ||
| KR1020160171842A KR102203229B1 (en) | 2016-01-08 | 2016-12-15 | Pharmaceutical composition with improved dissolution rate comprising nebivolol |
| PCT/KR2016/014771 WO2017119629A1 (en) | 2016-01-08 | 2016-12-16 | Pharmaceutical composition comprising nebivolol with improved dissolution rate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY201954A true MY201954A (en) | 2024-03-25 |
Family
ID=59430720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018702352A MY201954A (en) | 2016-01-08 | 2016-12-16 | Pharmaceutical composition comprising nebivolol with improved dissolution rate |
Country Status (6)
| Country | Link |
|---|---|
| KR (1) | KR102203229B1 (en) |
| CN (1) | CN108463250B (en) |
| AU (1) | AU2016385282B2 (en) |
| CA (1) | CA3010857C (en) |
| MX (1) | MX381515B (en) |
| MY (1) | MY201954A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025531213A (en) * | 2022-09-14 | 2025-09-19 | 上海雲晟研新生物科技有限公司 | Composition of nebivolol and amlodipine, its preparation method and application |
| WO2025202837A1 (en) * | 2024-03-23 | 2025-10-02 | Althera Laboratories India Pvt. Ltd. | Palatable icosapent ethyl formulation with statin and method thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101022791B (en) * | 2004-06-04 | 2011-11-16 | 麦兰实验室公司 | Compositions containing nebivolol |
| US8604222B2 (en) * | 2004-07-30 | 2013-12-10 | Forest Laboratories Holdings Limited | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol |
| NZ560386A (en) * | 2005-01-31 | 2009-12-24 | Mylan Lab Inc | Pharmaceutical composition comprising hydroxylated nebivolol |
| EP2174658A1 (en) * | 2005-05-31 | 2010-04-14 | Mylan Laboratories, Inc | Compositions comprising nebivolol |
| CN100508971C (en) * | 2007-03-30 | 2009-07-08 | 北京福瑞康正医药技术研究所 | Medicine composition possessing vasodilation and beta1 receptor blocking effects |
| FR2920311B1 (en) * | 2007-08-31 | 2010-06-18 | Galenix Innovations | SOLID COMPOSITION, ORODISPERSIBLE AND / OR DISPERSIBLE, WITHOUT A KNOWLEDGE EXCIPIENT AND PROCESS FOR PREPARING THE SAME |
| CN101361720A (en) * | 2008-10-08 | 2009-02-11 | 刘全胜 | Nebivolol hydrochloric acid orally disintegrating tablet and preparation method thereof |
| US20100143486A1 (en) * | 2008-12-10 | 2010-06-10 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| WO2011028016A2 (en) * | 2009-09-04 | 2011-03-10 | 한올바이오파마주식회사 | Pharmaceutical preparation comprising beta-adrenergic blockers and angiotensin ii receptor blockers |
| GB201003766D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| KR20110117758A (en) * | 2010-04-22 | 2011-10-28 | 한올바이오파마주식회사 | Pharmaceutical formulations containing beta adrenergic blockers and HMV-COA reductase inhibitors |
| KR20110130872A (en) * | 2010-05-28 | 2011-12-06 | 현대약품 주식회사 | Pharmaceutical composition and preparation method comprising crystalline nebivolol |
| CN102304103A (en) * | 2011-06-03 | 2012-01-04 | 郑州泰基鸿诺药物科技有限公司 | Fenofibrate acid salt, preparation method, pharmaceutical composition and application |
| US20140057954A1 (en) * | 2012-08-22 | 2014-02-27 | Forest Laboratories Holdings Ltd. | Chemical composition |
| CN103860492A (en) * | 2012-12-18 | 2014-06-18 | 重庆福安药业集团庆余堂制药有限公司 | Nebivolol hydrochloride oral solid drug composition and preparation method thereof |
| CN104688708B (en) * | 2013-12-06 | 2017-06-23 | 北京万生药业有限责任公司 | A kind of preparation method of Atorvastatin calcium preparation |
| CN103655454A (en) * | 2013-12-27 | 2014-03-26 | 辽宁亿灵科创生物医药科技有限公司 | Lansoprazole drug composition |
| CN103816124B (en) * | 2014-03-19 | 2016-08-17 | 国药集团致君（深圳）制药有限公司 | A kind of esomeprazole pastille pellet composition and preparation method thereof |
-
2016
- 2016-12-15 KR KR1020160171842A patent/KR102203229B1/en active Active
- 2016-12-16 CN CN201680078111.1A patent/CN108463250B/en active Active
- 2016-12-16 MY MYPI2018702352A patent/MY201954A/en unknown
- 2016-12-16 CA CA3010857A patent/CA3010857C/en active Active
- 2016-12-16 MX MX2018008443A patent/MX381515B/en unknown
- 2016-12-16 AU AU2016385282A patent/AU2016385282B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016385282A2 (en) | 2018-10-11 |
| MX2018008443A (en) | 2019-05-30 |
| CA3010857C (en) | 2020-09-15 |
| CN108463250B (en) | 2021-07-30 |
| CA3010857A1 (en) | 2017-07-13 |
| AU2016385282B2 (en) | 2019-11-21 |
| AU2016385282A1 (en) | 2018-08-23 |
| MX381515B (en) | 2025-03-12 |
| KR20170083484A (en) | 2017-07-18 |
| CN108463250A (en) | 2018-08-28 |
| KR102203229B1 (en) | 2021-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550341A1 (en) | Niraparib formulations | |
| PH12017502092A1 (en) | Topical pharmaceutical compositions | |
| MX2021004431A (en) | Novel processes. | |
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| PH12017501421A1 (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| EA201690287A1 (en) | 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY | |
| JOP20180071B1 (en) | Use of aminoalkylbenzothiazepine derivatives | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| WO2017022962A8 (en) | Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient | |
| MX2020007554A (en) | Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate. | |
| HK1215191A1 (en) | Low dose pharmaceutical composition | |
| MY163235A (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
| MY179605A (en) | Use of benzimidazole-proline derivatives | |
| MX2023011203A (en) | Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder. | |
| PH12016501519B1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| PH12015501945A1 (en) | Formulations of organic compounds | |
| MX2015017879A (en) | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase. | |
| SG11201908234WA (en) | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer | |
| MY201954A (en) | Pharmaceutical composition comprising nebivolol with improved dissolution rate | |
| MX2021004551A (en) | Pharmaceutical composition for treating aplastic anemia. | |
| NZ751972A (en) | Treatment of prurigo nodularis | |
| PH12021551396A1 (en) | Active ester derivatives of testosterone, compositions and uses thereof | |
| WO2016195194A3 (en) | Novel tlr2 antagonists | |
| EA202091561A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING PHARMACEUTICALLY ACCEPTABLE ACID-ADDITIVE LENALIDOMIDE SALT |